Wednesday, October 24th, 8:30-9:55am
Large biotech companies have shown a great interest in China, but have a short history in the country and limited ground operations. How should a Western biotech go about establishing a presence in China? Which operational strategies will allow them to get their innovative therapies into the hands of Chinese patients? A panel of biotech industry experts “trying to figure it out” will share their insights.
- Rajesh Parekh, Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company
- Boon Heon Tan, Managing Director, Biogen Idec, China
- Alec Reynolds, Commercial Director, Celgene Corporation
Boon Heon Tan
Tan Boon Heon is the Managing Director of Biogen Idec * China/Asia Expansion Markets, a region covering Greater China (China, Taiwan, Hong Kong), Korea and Southeast Asia. He is responsible for the commercial success, operational excellence and management of the teams in this region, and committed to introducing Biogen Idec’s pipeline of important specialty and rare disease drugs to these countries progressively.
Boon is an experienced pharmaceutical executive with a unique international experience spanning HQ, regional and country operations. He was previously with Merck, Sharp & Dohme (“MSD”), through its acquisition of Schering-Plough (“SP”), for more than 10 years. Boon’s former roles in MSD/SP included US Sales and Global Marketing, Asia-Pacific regional leadership, as well as various roles in China since 2008, including Head of Marketing, Regional General Manager of Shanghai, and Customer Solutions Director.
Prior to joining Biogen Idec in April 2012, Boon had a short stint with HR Consultancy firm Russell Reynolds as the head of the healthcare practice in China.
Boon started his professional career as a government official in the Singapore Economic Development Board, where he was last Assistant Head of the Life Sciences Division. In that role, Boon worked with other government agencies and companies to develop a world-class life sciences industry in Singapore.
A native Singaporean who is fluent in English and Mandarin Chinese, Boon holds Bachelors and Masters of Science in Engineering (Bioengineering) degrees from the University of Pennsylvania. He is a commissioned infantry officer in the Singapore Armed Forces and still holds a reserve appointment. Boon is married and lives in Shanghai with his wife.
Rajesh (Raj) is the leader of McKinsey’s Asia Pharmaceuticals and Medical Products Practice. He joined McKinsey’s Chicago office in 1996 and since 2005 has worked in our Shanghai office. He serves clients across the pharmaceutical and medical device and equipment sectors on their Asian businesses, with a focus on China, India, and Japan. Raj’s work spans a range of areas including growth strategy, sales & marketing and R&D. Raj led McKinsey’s internal knowledge effort to assess the impact of the recent healthcare reform on the medical device and equipment industry in China.
Recent medical device and equipment experience includes working with a global implantable medical device leader to develop breakthrough growth strategies for China and India; helping a leading hospital infusion equipment player assess attractiveness of the “value segment” in China and develop product and customer segmentation approach to capture the most attractive opportunities; and working with a leading medical device company to develop organization blueprint to manage the emerging market set of countries.
Raj holds a PhD in Chemical Engineering from University of Illinois at Urbana-Champaign and a BS in Chemical Engineering from University of California at San Diego.
Alec C. Reynolds is the Commercial Director of Celgene China. He joined Celgene in 2007. He has held several marketing roles for REVLIMID® and has led the global marketing business planning function. Previously, Alec worked for The Carlyle Group, a global private equity firm, and Morgan Stanley & Co. He received an AB degree from Princeton University and an MBA from the University of Virginia Darden School.